Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR known ✓ | P41180 | 4/20 | 0.55 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.46 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.46 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.46 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.46 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.46 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.46 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.46 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.46 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.46 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.46 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.46 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.46 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.46 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.46 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.46 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.44 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27497469 | 1.00 | CASR (0.55) | CASRPOLBSMN1; SMN2ADRA2CSLC6A2 | |
| SCHEMBL9047830 | 0.99 | CASR (0.54) | CASRPOLBSMN1; SMN2ADRA2CSLC6A2 | |
| Hydrochloric Acid SCHEMBL3082165 | 0.88 | CASR (0.60) | CASRPOLBSMN1; SMN2ADRA2CSLC6A2 | |
| Hydrochloric Acid SCHEMBL607723 | 0.88 | CASR (0.60) | CASRPOLBSMN1; SMN2ADRA2CSLC6A2 | |
| Hydrochloric Acid SCHEMBL31355096 | 0.88 | CASR (0.60) | CASRPOLBSMN1; SMN2ADRA2CSLC6A2 | |
| Hydrochloric Acid SCHEMBL3067899 | 0.88 | CASR (0.60) | CASRPOLBSMN1; SMN2ADRA2CSLC6A2 | |
| SCHEMBL15131260 | 0.87 | CASR (0.52) | CASRPOLBADRA2CSLC6A2HTR2C | |
| SCHEMBL5193705 | 0.86 | POLB (0.61) | CASRPOLBADRA2CSLC6A2HTR2C | |
| SCHEMBL2341650 | 0.86 | POLB (0.61) | CASRPOLBADRA2CSLC6A2HTR2C | |
| SCHEMBL15131229 | 0.86 | POLB (0.61) | CASRPOLBADRA2CSLC6A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20060229470-A1 | Calcium receptor-active molecules | NPS PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| EP-1553078-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| CN-1192011-C | Calcium receptor-active arylalkyl amines | NPS PHARMA INC (US) | 2005-03-09 | — | — | CN | disclosed |
| EP-1466888-A1 | Calcium receptor-active arylalkyl amines | NPS PHARMACEUTICALS, INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-0724561-B1 | CALCIUM RECEPTOR-ACTIVE ARYLALKYL AMINES | NPS PHARMA INC (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1275635-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1203761-A2 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6313146-B1 | CAN BE USED FOR THERAPY OF DISEASES OR DISORDERS IN A PATIENT BY MODULATING ONE OR MORE INORGANIC ION RECEPTOR ACTIVITIES | NPS PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6211244-B1 | AROMATIC AMINES FOR COMPLEXING CALCIUM | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6031003-A | TREATING A PATIENT HAVING A DISEASE OR DISORDER TREATABLE BY MODULATING ACTIVITY OF CALCIUM RECEPTORS IN VITRO BY ADMINISTERING A CALCIMIMETIC COMPOUND DETERMINED BY THE CALCILYTIC BOVINE PARATHYROID CELL TEST; OSTEOPOROSIS | NPS PHARMACEUTICALS, INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-6011068-A | CARBOCYCLIC-ALKYL SECONDARY AMINES | NPS PHARMACEUTICALS, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-6001884-A | Calcium receptor-active molecules | NPS PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5962314-A | CERTAIN CELLS IN THE BODY RESPOND NOT ONLY TO CHEMICAL SIGNALS, BUT ALSO TO IONS SUCH AS EXTRACELLULAR CALCIUM IONS (CA.SUP.2+). THE INVENTION RELATES TO NUCLEIC ACIDS ENCODING SUCH RECEPTORS AND CELLS CONTAINING SUCH NUCLEIC ACIDS. | NPS PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5858684-A | CONTACTING RECOMBINANT CELL WITH TEST COMPOUND WHICH IS NOT VERAPAMIL OR GALLOPAMIL, DETERMINING ABILITY OF COMPOUND TO AFFECT ACTIVITIES OF INORGANIC ION RECEPTOR; DETERMINATION OF AGONIST AND ANTAGONIST DRUGS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5763569-A | POLYPEPTIDES AS CALCIUM RECEPTORS TO GENERATE ANTIBODIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US) | 1998-06-09 | — | — | US | disclosed |
| US-5688938-A | Calcium receptor-active molecules | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229470-A1 | Calcium receptor-active molecules | CASR, CALCR, ORAI1 | CASR 1/4885ADRA2C 1982/4885SLC6A2 3480/4885 |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | CASR, CALCR, ORAI1 | CASR 1/4885ADRA2C 1982/4885SLC6A2 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.